Services on Demand
On-line version ISSN 1414-431X
Braz J Med Biol Res vol.33 n.3 Ribeirão Preto Mar. 2000
Antimicrobial resistance patterns of Haemophilus influenzae isolated from patients with meningitis in São Paulo, Brazil
1Seção de Bacteriologia, Instituto Adolfo Lutz, São Paulo, SP, Brasil
2Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brasil
Material and Methods
Correspondence and Footnotes
From 1989 to 1995, a total of 391 Haemophilus influenzae isolates were recovered from the cerebrospinal fluid (CSF) of hospitalized patients in São Paulo, Brazil. The majority of strains were isolated from infants aged less than 5 years. Strains belonging to biotype I (64.7%), biotype II (34.5%) and biotype IV (0.76%) were detected. Ninety-nine percent of these strains were serotype b. Minimal inhibitory concentration (MIC) was determined for ampicillin, chloramphenicol and ceftriaxone. The ß-lactamase assay was performed for all strains. The rate of ß-lactamase producer strains ranged from 10 to 21.4% during a period of 7 years, with an overall rate of 13.8%. Of the 391 strains analyzed, none was ß-lactamase negative ampicillin resistant (BLNAR). A total of 9.7% of strains showed resistance to both ampicillin and chloramphenicol; however, 4% of them were resistant to ampicillin only and 2% to chloramphenicol. All strains were susceptible to ceftriaxone and the MIC90 was 0.007 µg/ml, suggesting that ceftriaxone could be an option for the treatment of bacterial meningitis in pediatric patients who have not been screened for drug sensitivity.
Key words: Haemophilus influenzae, meningitis, antimicrobial resistance
Meningitis, especially in infants, young children and in the elderly, is the most serious clinical manifestation of invasive disease caused by Haemophilus influenzae (1,2). Substantial declines in invasive Haemophilus influenzae type b diseases have been reported in many countries where routine vaccination against H. influenzae type b has been implemented (3-6). Although very successful in developed countries, H. influenzae type b vaccination is still very costly and unfeasible in the majority of developing countries. In São Paulo State, Brazil, H. influenzae is the second most common cause of meningitis, mainly among infants aged less than 5 years. The average annual rate of incidence of meningitis caused by H. influenzae was 11.4 cases per 100,000 inhabitants from 1989 to 1995 (Respiratory Diseases Division, Epidemiological Surveillance Center, São Paulo, SP, Brazil).
Resistance to ampicillin due to a plasmid-mediated extracellular TEM-1 type ß-lactamase was recognized in H. influenzae for the first time in 1974 (7-9). Subsequently, strains producing a second ß-lactamase named ROB-1 enzyme were reported (10). More recently, H. influenzae strains referred to as ß-lactamase negative ampicillin resistant (BLNAR) have also been described, although such strains seem to be relatively uncommon as shown by recent national and multinational surveillance studies (2,11-14).
The prevalence of ampicillin resistance in H. influenzae strains has been the subject of multinational surveillance studies in several countries and the overall rate reported was between 10 and 60% (8,9,11-14). The emergence of resistant H. influenzae strains, particularly to ampicillin, all over the world has limited the routine use of ampicillin and as a result third-generation cephalosporins have become a therapeutic option (15,16).
Few data are available in Brazil on ampicillin resistance and ß-lactamase production in H. influenzae isolated from young children. In the present study we report the antimicrobial resistance pattern of H. influenzae isolated chiefly from young children in São Paulo, Brazil, from 1989 through 1995.
A total of 391 H. influenzae strains isolated between 1989 and 1995 were studied. All strains were isolated from cerebrospinal fluid (CSF) samples, 76% of them from infants aged less than 5 years and hospitalized in São Paulo municipality. These strains and CSF were sent by hospital laboratories to the National Center for Meningitis, Adolfo Lutz Institute, Central Public Health Laboratory, São Paulo, Brazil, for routine microbiological analysis.
Isolates were identified by colony and cell morphology and by the demonstration of growth requirements for V and X factors. The V requirement was tested by observing the satellite phenomenon and the X factor dependence was determined by testing the ability to convert d-aminolevulinic acid to porphyrins. Strains were further characterized by biochemical reactions using the method described by Kilian and Biberstein (17). Capsulated strains were serotyped by the method of Pitman (18) using slide agglutination with type-specific antisera a through f.
All strains were subcultured twice onto a chocolate agar plate (Difco Laboratories, Detroit, MI, USA) and incubated at 37°C in 5% CO2 for 18-24 h before testing. The minimal inhibitory concentrations (MIC) of different antimicrobial agents were determined by the broth microdilution method using Haemophilus test medium (HTM) (Cation-supplemented Mueller-Hinton Broth, BBL Microbiology Systems, Cockeysville, MD, USA), supplemented with 15 µg/ml of bovine hematin, 15 µg/ml of NAD and 5 µg/ml of yeast extract (Difco Laboratories), containing one of the following antimicrobial agents at 2-fold dilution: 0.03-32 µg/ml ampicillin, 0.015-16 µg/ml chloramphenicol, 0.001-2 µg/ml ceftriaxone (19) (Sigma Chemical Co., St. Louis, MO, USA). Antibiotic panels were prepared by dispensing media containing two-fold concentration increments of antimicrobial agents in a 50-µl volume into plastic 96-well trays (Difco). Growth from 18- to 24-h cultures was suspended in distilled water and diluted to match the turbidity, this being equivalent to 0.5 McFarland standard read using a spectrophotometer at 625 nm. The suspension was further diluted 1:100 and added to the dilution trays to achieve a final inoculum of 5 x 105 CFU/ml.
Colony counts were performed to determine the desired final inoculum (19). Immediately following inoculation, the microdilution panel was incubated at 37°C in ambient air for 20 to 24 h. After incubation the MIC was defined as the lowest concentration of an antimicrobial agent required for an organism to show no evidence of growth. According to the NCCLS criteria (19), the organisms were considered resistant/susceptible if the MIC was ³/£ (µg/ml) 4/1 for ampicillin and 8/2 for chloramphenicol, and susceptible if the MIC was £2 µg/ml for ceftriaxone. Haemophilus influenzae ATCC 49247 was used as control.
Production of ß-lactamase was determined by the chromogenic cephalosporin method (7) using reconstituted lyophylized nitrocefin (Glaxo 87/312 Glaxo Research, Unipath Ltd., Hampshire, England). The test was considered positive if the color changed from yellow to purple for cephalosporin. Haemophilus influenzae ATCC 49247 was used as negative control and Staphylococcus aureus ATCC 29213 as positive control.
Biotypes and serotypes
Strains belonging to biotype I 253 (64.7%), biotype II 135 (34.5%) and biotype IV 3 (0.76%) were detected. Type b was the serotype accounting for 99% of strains.
Antimicrobial resistance patterns
The annual percentage of resistant strains is shown in Table 1. The overall rate of ampicillin-resistant strains that produced ß-lactamase was 13.8%. The percentage of ß-lactamase producer strains isolated was 14.0% for children aged less than 5 years and 1.6% for children older than 6 years. This difference was not statistically significant, as demonstrated by the chi-square test (P = 0.3). Resistance to both ampicillin and chloramphenicol was observed in 9.7% (38/391) of strains. Strains isolated in 1993 showed the highest rate of ß-lactamase-producing strains (21.4%) and also of strains resistant to both chloramphenicol and ampicillin (14.2%). The overall rate of strains resistant only to chloramphenicol was 2.0%, and the overall rate of strains resistant only to ampicillin was 4.0%. Among the 391 strains analyzed, none was BLNAR. Data concerning the MIC50 and MIC90 of ß-lactamase-positive and -negative strains are summarized in Table 2. All H. influenzae strains were extremely susceptible to ceftriaxone, exhibiting MIC90 values of 0.007 µg/ml (Table 2).
Since the late 1970's, antibiotic resistance has increased among strains of H. influenzae, mainly in terms of ß-lactamase-mediated ampicillin resistance, representing a serious clinical concern all over the world. The present study shows that the overall rate of ß-lactamase producers in H. influenzae was 13.8%. Similar results have also been obtained in a collaborative study conducted in the US during the 80's and in São Paulo during the 90's (20,21). In Finland and in South Africa the overall rate of ß-lactamase-mediated ampicillin resistance in H. influenzae was 10% (11,22,23).
The ß-lactamase-producing strains presented a MIC90 of 32 µg/ml for ampicillin and 16 µg/ml for chloramphenicol, with most strains resistant to ampicillin being also resistant to chloramphenicol (Table 1). The resistance to ampicillin is coded by a plasmid which harbors the transposon TnA, and the transposition mechanism is important for the evolution to plasmids simultaneously carrying multiple resistance (24,25). Significant changes in MIC90 values over a period of time could be the best indicators of increasing resistance to the ß-lactam antibiotics in H. influenzae (24).
The overall rates of ß-lactamase production were highest in the age groups of less than 5 years and among isolates from systemic sources such as CSF. These observations could be explained by the relatively higher percentage of H. influenzae strains isolated from young children. Non-ß-lactamase-mediated ampicillin resistance was not detected among the H. influenzae strains studied. This is in agreement with numerous previous surveillance studies, which have indicated that such observations remain uncommon (11,13,14). It has been postulated that BLNAR is associated with altered penicillin-binding proteins (PBPs) and might be due to a lower virulence of strains with abnormal PBPs (13,16,26).
Although in the 80's it was reported that 57% of H. influenzae strains isolated in Spain were ampicillin and chloramphenicol resistant, resistance to chloramphenicol only is still rare (8,9,14,21). Among our strains, 11.7% were resistant to chloramphenicol, including the associated resistance to ampicillin (9.7%), and 2% were resistant only to chloramphenicol. In addition, MIC90 to chloramphenicol showed the same range (8-16 µg/ml), in agreement with data reported in other countries (8,27). Our data indicate that 9.7% of all strains were resistant both to ampicillin and chloramphenicol, in agreement with reported results (21).
The rapid detection of resistance and early initiation of alternative therapy are important factors in the treatment of meningitis caused by multiple resistance strains. It is of fundamental importance to perform the ß-lactamase test and susceptibility tests in order to detect resistance to ampicillin and chloramphenicol. No relationship between antimicrobial resistance patterns and biotypes was seen in our study, as also reported elsewhere (23,28). We observed a higher frequency of biotype I among strains isolated from invasive disease mainly affecting children, as also reported previously (29).
All strains were susceptible to ceftriaxone with a MIC90 of 0.007 µg/ml for ß-lactamase-positive and -negative strains. In developed countries, the alternative treatment of choice for meningitis caused by multiple resistant H. influenzae strains is the use of third-generation cephalosporins (11-13). In several countries resistance to ampicillin and chloramphenicol was found to be sufficiently high to warrant their replacement by a combination of ampicillin with a ß-lactamase inhibitor, e.g., sulbactam or a third-generation cephalosporin as first-line therapy, depending on the severity of infection (8,15,22-24).
In Brazil there is a need for further evaluation of the resistance profile in H. influenzae to ensure a better therapy option, especially where the combination of ampicillin and chloramphenicol is extensively applied because of its low cost and effectiveness (23,30,31).
The emergence of drug resistance is a serious challenge for the management of invasive H. influenzae disease, which emphasizes the fundamental role of laboratory-based surveillance for antimicrobial resistance. The continued usefulness of antimicrobial agents will probably depend on the rational use of antimicrobial agents in the community.
We showed an increasing antimicrobial resistance to ampicillin and chloramphenicol among Haemophilus influenzae strains isolated from children. Since all strains were susceptible to ceftriaxone, we conclude that this antimicrobial agent could be an option for the treatment of bacterial meningitis in pediatric patients who have not been screened for drug sensitivity.
1. Jordens JZ & Slack MPE (1995). Haemophilus influenzae: Then and now. European Journal of Clinical Microbiology and Infectious Diseases, 14: 935-948. [ Links ]
2. Scriver SR, Hoban DJ, McGeer A, Moore TC, Walmsley SL & Low DE (1994). Surveillance of susceptibility testing methodologies for Haemophilus influenzae in Canada, including evaluation of disk diffusion test. Journal of Clinical Microbiology, 32: 2013-2015. [ Links ]
3. Peltola H, Kilpi T & Anttila M (1992). Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet, 340: 592-594. [ Links ]
4. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, Wenger JD & the Haemophilus influenzae Study Group (1993). Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. Journal of the American Medical Association, 269: 221-226. [ Links ]
5. Teare EL, Fairley CK, White J & Begg NT (1994). Efficacy of Hib vaccine. Lancet, 344: 828-829. [ Links ]
6. Wenger JD (1994). Impact of Haemophilus influenzae type b vaccines on the epidemiology of bacterial meningitis. Infectious Agents and Diseases, 2: 324-332. [ Links ]
7. Sykes RB (1978). Methods for detecting betalactamase. In: David SR, Ian P, David W & Richard W (Editors), Laboratory Methods in Antimicrobial Chemotherapy. Churchill Livingstone, Edinburgh, 64-69. [ Links ]
8. Campos J, Torne SG, Gairi JMJ & Fabregues I (1986). Multiple resistant Haemophilus influenzae type b causing meningitis: Comparative clinical and laboratory study. Journal of Pediatric, 108: 897-902. [ Links ]
9. Bijlmer HA, van Alphen L, Greenwood BM, van den Broek LG, Valkenburg HÁ & Dankert J (1994). Antibiotic susceptibility of invasive and non-invasive isolates of Haemophilus influenzae from the Gambia, West Africa. Journal of Antimicrobial Chemotherapy, 34: 275-280. [ Links ]
10. Markowitz SM (1980). Isolation of ampicillin resistant production strain of Haemophilus influenzae. Antimicrobial Agents and Chemotherapy, 17: 80-83. [ Links ]
11. Jorgensen JH, Doern GV, Maher LA, Howell AW & Redding JA (1990). Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Journal of Clinical Microbiology, 34: 2075-2080. [ Links ]
12. Powell M, McVey D, Kassim MH, Chen HY & Williams JD (1991). Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Brahamella) catarrhalis isolated in the UK from sputa. Journal of Antimicrobial Chemotherapy, 28: 249-259. [ Links ]
13. Nissinen A, Herva E, Katila ML, Kontiainen S, Liimatainen O, Oinonen S, Takala AK & Huovinen P (1995). Antimicrobial resistance in Haemophilus influenzae isolated from blood, cerebrospinal fluid, middle ear fluid and throat samples of children. A nationwide study in Finland in 1988-1990. Scandinavian Journal of Infectious Diseases, 27: 57-61. [ Links ]
14. Doern GV & the Alexander Project Collaborative Group (1996). Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 Western Europe and USA collaborative surveillance study. Journal of Antimicrobial Chemotherapy, 38: 59-69. [ Links ]
15. Bryan JP, Silva HR, Tavares A, Rocha L & Sheld WM (1990). Etiology and mortality of bacterial meningitis in Northeastern Brazil. Reviews of Infectious Diseases, 12: 128-135. [ Links ]
16. Williams JD & Moosdeen J (1986). Antibiotic resistance in Haemophilus influenzae: epidemiology, mechanisms, and therapeutic possibilities. Reviews of Infectious Diseases, 8: S555-S561. [ Links ]
17. Kilian M & Biberstein EL (1984). Haemophilus. In: Noel RK & John GH (Editors), Bergey's Manual of Systematic Bacteriology. Williams & Wilkins, Baltimore, USA, 558-569. [ Links ]
18. Pitman M (1931). Variation and type specificity in the bacterial species Haemophilus influenzae. Journal of Experimental Medicine, 53: 471-492. [ Links ]
19. National Committee for Clinical Laboratory Standards (NCCLS) (1997). Performance standards for antimicrobial susceptibility testing. 4th edn. Information Suppl M100 S5. Approved standard. NCCLS, Vilanova, PA. [ Links ]
20. Doern GV, Jorgensen JH, Thornsberry C, Preston DA & the Haemophilus influenzae Surveillance Group (1986). Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagnostic Microbiology and Infectious Diseases, 4: 95-107. [ Links ]
21. Rey LC & Farhat CK (1997). Prevalência de Haemophilus influenzae resistentes a ampicilina, cefaclor, cefotaxime, cloranfenicol e cotrimoxazol isolados de laboratórios na cidade de São Paulo. Jornal de Pediatria, 73: 26-31. [ Links ]
22. Manninen R, Huovinen P, Nissinen A & Finnish Study Group for Antimicrobial Resistance (1997). Increased antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Finland. Journal of Antimicrobial Chemotherapy, 40: 387-392. [ Links ]
23. Hussey G, Hitchcock J, Hanslo D, Coetzee G, Van Shalkwyk E, Pitout J & Schaaf H (1994). Serotypes and antimicrobial susceptibility of Haemophilus influenzae. Journal of Antimicrobial Chemotherapy, 34: 1031-1036. [ Links ]
24. James PA, Lewis DA, Jordens JZ, Cribb J, Dawson SJ & Murray SA (1996). The incidence and epidemiology of ß-lactam resistance in Haemophilus influenzae. Journal of Antimicrobial Chemotherapy, 37: 737-746. [ Links ]
25. Brunton J, Clare D & Meier MA (1986). Molecular epidemiology of antibiotic resistance plasmids of Haemophilus species and Neisseria gonorrhoeae. Reviews of Infectious Diseases, 8: 713-724. [ Links ]
26. Rubin LG, Mendelman PM, Rakita RM & Rosen H (1991). Virulence of non-ß-lactamase-mediated ampicillin-resistant Haemophilus influenzae. FEMS Microbiological Letters, 84: 27-32. [ Links ]
27. Givner LB, Abramson JS & Wasilauskas B (1989). Meningitis due to Haemophilus influenzae type b resistant to ampicillin and chloramphenicol. Reviews of Infectious Diseases, 11: 329-334. [ Links ]
28. Long SS, Teter MJ & Gilligan PH (1983). Biotype of Haemophilus influenzae: correlation with virulence and ampicillin resistance. Journal of Infectious Diseases, 147: 800-806. [ Links ]
29. Landgraf IM & Vieira MFP (1993). Biotypes and serotypes of Haemophilus influenzae from patients with meningitis in the city of São Paulo, Brazil. Journal of Clinical Microbiology, 31: 743-745. [ Links ]
30. Guia de Vigilância Epidemiológica (1998). Meningites em geral (Cap. 5.20). Ministério da Saúde. Fundação Nacional de Saúde, Brasília. [ Links ]
31. Freire HBM & Freire LMS (1994). Aspectos atuais do tratamento das meningites bacterianas. Revista Médica de Minas Gerais, 4: 37-38. [ Links ]
We thank Dr. Kinue Irino for useful comments and for revising the manuscript, and Dr. Eliseu Waldman for advice regarding the manuscript. We are also indebted to Dr. Carmo Elias A. Melles, Meningitis Reference Center Coordinator, for valuable assistance, to Maria C. Cunto Brandeleone for encouragement, and to Rosemeire Cobo Zanella for supplying the antisera. We acknowledge the State Hospital network for promptly sending the strains and cerebrospinal fluid samples, many of them received from Instituto de Infectologia Emílio Ribas.
Address for correspondence: S.T. Casagrande, Seção de Bacteriologia, Instituto Adolfo Lutz, Av. Dr. Arnaldo, 351, 01246-902 São Paulo, SP, Brasil. E-mail: email@example.com
Publication supported by FAPESP. Received March 3, 1999. Accepted December 17, 1999.